Yu Minshu相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment

贝伐单抗联合索拉非尼治疗复发性卵巢癌患者的II期临床试验，患者既往是否接受过贝伐单抗治疗

期刊:Gynecologic Oncology

影响因子:4.1

doi:10.1016/j.ygyno.2020.07.031

Lee, Jung-Min; Annunziata, Christina M; Hays, John L; Cao, Liang; Choyke, Peter; Yu, Minshu; An, Daniel; Turkbey, Ismail Baris; Minasian, Lori M; Steinberg, Seth M; Chen, Helen; Wright, John; Kohn, Elise C

发表日期：2020

文献求助收藏

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer

奥拉帕尼联合卡铂治疗三阴性乳腺癌女性患者的 I/Ib 期研究

期刊:Oncotarget

doi:10.18632/oncotarget.16577

Lee, Jung-Min; Hays, John L; Chiou, Victoria L; Annunziata, Christina M; Swisher, Elizabeth M; Harrell, Maria I; Yu, Minshu; Gordon, Nicolas; Sissung, Tristan M; Ji, Jiuping; Figg, William D; Minasian, Lori; Lipkowitz, Stanley; Wood, Bradford J; Doroshow, James; Kohn, Elise C

发表日期：2017

文献求助收藏

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer

CECs 和 IL-8 在复发性铂敏感卵巢癌患者中具有预后和预测价值：来自奥拉帕尼联合西地尼布与奥拉帕尼单药治疗复发性铂敏感卵巢癌的随机 II 期试验的生物标志物相关性

期刊:Frontiers in Oncology

影响因子:3.3

doi:10.3389/fonc.2015.00123

Lee, Jung-Min; Trepel, Jane B; Choyke, Peter; Cao, Liang; Sissung, Tristan; Houston, Nicole; Yu, Minshu; Figg, William D; Turkbey, Ismail Baris; Steinberg, Seth M; Lee, Min-Jung; Ivy, S Percy; Liu, Joyce F; Matulonis, Ursula A; Kohn, Elise C

发表日期：2015

文献求助收藏

Feasibility and safety of sequential research-related tumor core biopsies in clinical trials

在临床试验中，连续进行研究相关肿瘤核心活检的可行性和安全性

影响因子:5.1

doi:10.1002/cncr.27916

Lee, Jung-min; Hays, John L; Noonan, Anne M; Squires, Jennifer; Minasian, Lori; Annunziata, Christina; Wood, Bradford J; Yu, Minshu; Calvo, Katherine R; Houston, Nicole; Azad, Nilofer; Kohn, Elise C

发表日期：2013

文献求助收藏

Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome

卵巢癌积液中黏附分子蛋白特征可预测患者预后

影响因子:5.1

doi:10.1002/cncr.26449

Kim, Geoffrey; Davidson, Ben; Henning, Ryan; Wang, Junbai; Yu, Minshu; Annunziata, Christina; Hetland, Thea; Kohn, Elise C

发表日期：2012

文献求助收藏

Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.

前粒蛋白是晚期上皮性卵巢癌的潜在预后生物标志物

期刊:Gynecologic Oncology

影响因子:4.1

doi:10.1016/j.ygyno.2010.09.006

Han Jasmine J, Yu Minshu, Houston Nicole, Steinberg Seth M, Kohn Elise C

发表日期：2011

文献求助收藏

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

凡德他尼旨在抑制 VEGFR2 和 EGFR 信号传导，但作为复发性卵巢癌的单药疗法，它没有临床疗效，也没有检测到对 VEGFR2 的调节作用

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-09-2308

Annunziata Christina M, Walker Amanda J, Minasian Lori, Yu Minshu, Kotz Herbert, Wood Bradford J, Calvo Katherine, Choyke Peter, Kimm Daniel, Steinberg Seth M, Kohn Elise C

发表日期：2010

文献求助收藏

Susceptibility of rats to mammary gland carcinogenesis by the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) varies with age and is associated with the induction of differential gene expression

大鼠对食物来源致癌物2-氨基-1-甲基-6-苯基咪唑并[4,5-b]吡啶（PhIP）诱发乳腺癌的敏感性随年龄而变化，并与差异基因表达的诱导有关。

期刊:American Journal of Pathology

影响因子:3.6

doi:10.1016/S0002-9440(10)63288-9

Shan, Liang; Yu, Minshu; Schut, Herman A J; Snyderwine, Elizabeth G

发表日期：2004

文献求助收藏

Id4 regulates mammary epithelial cell growth and differentiation and is overexpressed in rat mammary gland carcinomas

Id4调控乳腺上皮细胞的生长和分化，并在大鼠乳腺癌中过度表达。

期刊:American Journal of Pathology

影响因子:3.6

doi:10.1016/S0002-9440(10)63604-8

Shan, Liang; Yu, Minshu; Qiu, Cunping; Snyderwine, Elizabeth G

细胞生物学

发表日期：2003

文献求助收藏